Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – CGTN
The potential vaccine appeared to be safe and can trigger an immune response.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
Noosa News22 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’
-
Noosa News22 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
General19 hours agoRussia launches hundreds of drones and missiles against Ukraine in fresh attack
-
Business11 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?